Novartis announced that patupilone (EPO906) did not show a significant overall survival advantage in a phase III trial of patients with advanced ovarian cancer, refractory or resistant to platinum-based therapy The comparator arm in the trial was Doxil®/Caelyx® (pegylated liposomal doxorubicin). Investigators involved in the study and regulatory agencies have been notified of the trial outcome. No new or unexpected serious adverse events in the patupilone arm were identified in the trial. Novartis does not plan to proceed with regulatory filings based on these data…

Excerpt from:
Novartis Phase III Trial Examining EPO906 (patupilone) For Patients With Advanced Ovarian Cancer Failed To Meet Primary Endpoint

You may also like:

• Novartis Announces Extension Of US Regulatory Priority Review Period For FTY720, An Investigational Once-daily Oral Multiple Sclerosis Therapy
• Pfizer Statement On Conducting Clinical Trial
• AstraZeneca Announces Results Of Recentin HORIZON II Phase III Trial In Metastatic Colorectal Cancer
• New Phase II Study Showed Trastuzumab-DM1 Shrank Tumors In Women With Highly Advanced HER2-Positive Breast Cancer
• Circumcising Men With HIV Did Not Protect Women, Trial Stopped Early
• AIBN And US Researchers Join Forces, Australia
• Arizona Heart Institute Enrolls First Patient In Anaconda(TM) Investigational Study For The Treatment Of Abdominal Aortic Aneurysm
• Cephalon Provides Clinical Update On Lestaurtinib In Relapsed Acute Myelogenous Leukemia
• Phase 3 ILLUMINATE Study Supports 24-Week Telaprevir-Based Therapy Within A Response-Guided Regimen For People With Hepatitis C
• Repros Requests Type B Meeting With FDA To Discuss Phase III Protocols For Androxal(R)